All material subject to strictly enforced copyright laws. © 2022 Euromoney Institutional Investor PLC group
Corporate Bonds

Teva’s M&A swoop brings in the crowds as buyers scramble for new paper

Teva Shaom PA 230x150

Israeli-American pharmaceutical company Teva ripped through a severely undersupplied European corporate bond market this week, making savage price cuts on all three tranches of a €4bn trade that still ground tighter in secondary markets. Ross Lancaster reports.

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Take a Free Trial or Login
We use cookies to provide a personalized site experience.
By continuing to use & browse the site you agree to our Privacy Policy.
I agree